Pharmacological Class:
CNS stimulant.

Active Ingredient(s):
Amphetamine sulfate 5mg, 10mg; tablets.

Company
Arbor Pharmaceuticals, Inc.
Indication(s):
Attention deficit hyperactivity disorder (ADHD). Narcolepsy. Short-term adjunct in managing exogenous obesity.

Pharmacology:
Amphetamines are non-catecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures, and weak bronchodilator, and respiratory stimulant action.

Amphetamine in the racemic form differs from dextroamphetamine in that the l-isomer is more potent than the d-isomer in cardiovascular activity, but much less potent in causing CNS excitatory effects. The racemic mixture is also less effective as an appetite suppressant when compared to dextroamphetamine.

In treating obesity, it has not been established that the action is primarily appetite suppression; other CNS actions or metabolic effects may be involved. The origins of increased weight loss due to the various possible drug effects are not established.

Legal Classification:
CII

Contraindication(s):
Advanced arteriosclerosis. Symptomatic cardiovascular disease. Moderate-to-severe hypertension. Hyperthyroidism. History of drug abuse. Agitation. During or within 14 days of monoamine oxidase inhibitors (MAOIs). Hypersensitivity to sympathomimetics.

Adults & Children:
Individualize. Avoid late evening doses; give first dose upon awakening and additional doses at 4–6 hour intervals. ADHD: <3 years: not recommended. 3–5 years: initially 2.5mg daily, may increase by 2.5mg/day at weekly intervals. ≥6 years: initially 5mg once or twice daily; may increase by 5mg/day at weekly intervals; max 40mg/day. Narcolepsy: <6 years: not recommended. 6–12 years: initially 5mg daily, may increase by 5mg/day at weekly intervals. ≥12 years: initially 10mg daily; may increase by 10mg/day at weekly intervals. Usual range 5–60mg/day. Obesity: <12 years: not recommended. ≥12 years: take 30–60 minutes before meals. Usually up to 30mg/day in divided doses of 5–10mg.

Warnings/Precautions:
High abuse potential. Known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease: not recommended. Hypertension. Heart failure. Recent MI. Arrhythmias. Assess cardiovascular status. Psychosis. Bipolar disorder. Depression. Monitor for worsening of aggressive behavior or hostility. Seizure disorders; discontinue if occur. eva luate for tics or Tourette's syndrome prior to therapy. Peripheral vasculopathy including Raynaud's phenomenon; monitor for digital changes. Monitor HR, BP, growth in children. Reeva luate periodically. Write ℞ for smallest practical amount. Pregnancy (Category C). Nursing mothers: not recommended.

Interaction(s)
See Contraindications. Avoid concomitant antacids. Potentiated by alkalinizers (eg, sodium bicarbonate, acetazolamide, some thiazides), propoxyphene. Antagonized by acidifiers, chlorpromazine, haloperidol, lithium. May antagonize effects of adrenergic blockers, antihistamines, veratrum alkaloids, antihypertensives. May potentiate effects of tricyclic antidepressants, meperidine, norepinephrine. May delay absorption of phenytoin, phenobarbital, ethosuximide. Monitor effects with concomitant PPIs. Convulsions with propoxyphene overdose and amphetamines. May interfere with urinary steroid tests.

Adverse Reaction(s)
Palpitations, tachycardia, blood pressure increase, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, motor/phonic tics, Tourette's syndrome, dry mouth, unpleasant taste, diarrhea, constipation, anorexia, weight loss, urticaria, impotence, libido change, prolonged erection, rhabdomyolysis; serious cardiovascular events, visual disturbances.

How Supplied:
Tabs—100

LAST UPDATED:
7/17/2015